Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.43 |
| ▸ | CD38 | P28907 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16793163 | 0.78 | PRKCQ (0.55) | CD38PRKCQMEN1KMT2ATSHR | |
| SCHEMBL3844908 | 0.77 | PRKCQ (0.42) | DHFRCD38HDAC3PRKCQMEN1 | |
| SCHEMBL16796529 | 0.77 | KDM4C (0.44) | DHFRCD38HDAC3PRKCQMEN1 | |
| SCHEMBL15749318 | 0.75 | KDM4E (0.51) | DHFRHDAC3MAPTPKM | |
| SCHEMBL16797122 | 0.72 | CD38 (0.40) | DHFRCD38HDAC3PRKCQMEN1 | |
| SCHEMBL15540453 | 0.72 | CD38 (0.42) | CD38TSHR | |
| SCHEMBL3449998 | 0.72 | KDM4E (0.37) | TSHRMAPTHPGDHTT | |
| SCHEMBL18919003 | 0.70 | DHFR (0.44) | DHFRMAPT | |
| SCHEMBL15749399 | 0.70 | ADORA2A (0.39) | MEN1KMT2ACASP6MAPTHTT | |
| SCHEMBL15540167 | 0.70 | AAK1 (0.40) | DHFRCD38PRKCQKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920052-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-03-20 | — | — | US | disclosed |
| US-20170158688-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158688-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | DHFR 489/4885CD38 1623/4885HDAC3 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.